Endpoints News

Novo mulls buying a monthly GLP-1		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T Wed Th F

4 February, 2026

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

presented by

Biggest SCOPE Buzz: Two Disruptors in Clinical Research Are Redefining Enrollment Speed

news

Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo

Novartis expects generics to shave $4B from 2026 sales, as Entresto takes Q4 hit

Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio

Amgen says it doesn’t plan to pull its rare disease drug Tavneos, despite FDA ask

UK’s health department expected to spend £1B in pharma trade deal with US

Analyst – Life Sciences Strategy & Intelligence

Sedulo Group

Remote

Vice President, Investor Relations & Communications

C4 Therapeutics

Watertown, MA, USA

Recruit talent with Endpoints Careers

Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it

Novo cites MFN as disappointing 2026 sales forecast triggers selloff

'Turning around the Titanic': How the incoming PBM reforms will transform CMS

Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?

•

One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings

Ultragenyx unwraps data that may be central to its gene therapy resubmission

China startup AccurEdit raises $75M for gene editing therapies that show early promise

News Briefing

Daiichi ends work on an ADC; Layoffs at GSK's R&D unit

Exclusive: Stanford duo joins AI scientist race with startup backed by a16z and Menlo

AstraZeneca gets CRL for self-injectable pen version of lupus drug Saphnelo

More than one-third of cancer cases are preventable, massive study finds

10.

A ‘shadow CDC’ is scrambling to fill gaps in public health data

Scientific American

Lilly continues to outpace Novo in the obesity space, with the Indianapolis drugmaker beating 2025 sales projections by a healthy $1.2 billion. Meanwhile, Novo’s stock continues to falter after it warned shareholders yesterday that its 2026 sales are expected to decline.